fbpx
      How to Buy

          Video: German cannabis legalisation and potential tailwinds ahead of 2022

          German medical cannabis legalisation and potential tailwinds ahead of 2022

          What effect would a German Cannabis legalisation have on the broader European landscape?
           
          This is one of the many questions Florian Berberich (Associate Director DACH at Rize ETF) asked John Kagia, (Chief Knowledge Officer at New Frontier Data and thematic research partner of Rize ETF), during their 20-minute conversation.

          Furthermore, they also discussed topics like the development of the European cannabis landscape, the difference between the adult-use and Medical Cannabis market, and the requirements to run a successful liberal cannabis policy in which both industries exist alongside each other.

          Introduction

          (2:45) What is the difference between the adult-use and medical cannabis market?

          (6:25) What are the tailwinds that can be observed in the medical space coming from a legislation of adult use cannabis?

          (12:14) What is the European landscape looking like?

          (15:40) What does it take to run a liberal cannabis policy that has both a medical and an adult-use market?

          (20:05) What is the market outlook for Germany?

           

          Related ETF

          FLWR: Rize Medical Cannabis and Life Sciences UCITS ETF

          • 1
          • 2
          • 3

          Select Your Country

          United Kingdom
          Germany
          Italy
          Switzerland
          Austria
          Denmark
          Finland
          Ireland
          Luxembourg
          Netherlands
          Norway
          Spain
          Sweden

          Select Your Investor Type

          ======